QNCX

Business Context and Reporting Period

Quince Therapeutics, Inc. (QNCX) filed its Quarterly Report on Form 10-Q for the period ended June 30, 2026. The Company is a clinical-stage biopharmaceutical firm that recently pivoted its strategy following the failure of its lead asset, eDSP, and the acquisition of Orphai Therapeutics. On May 18, 2026, Quince completed the acquisition of Orphai, acquiring the lead asset LAM-001 (an inhaled rapamycin formulation) to treat pulmonary disorders. The Company also executed two reverse stock splits (1-for-10 in April 2026 and 1-for-20 in June 2026), with all historical data adjusted retrospectively.

Key Financial Metrics

Debt and Liquidity: As of June 30, 2026, the Company had no outstanding debt, having settled its European Investment Bank (EIB) loan in March 2026. The Company raised approximately $103.6 million in net proceeds from a May 2026 private placement of Series C Preferred Stock and $20.3 million from an ATM program during the six-month period.

Material Changes vs. Prior Period

• Acquisition Impact: Operating expenses increased significantly to $94.4 million (from $25.3 million) primarily due to a $59.0 million charge for acquired in-process research and development (IPR&D) related to the Orphai Acquisition and a $67.8 million impairment charge on legacy intangible assets (eDSP program).
• Non-Cash Adjustments: The Net Loss was mitigated by a $64.3 million gain from the reduction of contingent consideration liabilities (due to the discontinuation of the eDSP program) and a $35.6 million gain from fair value adjustments on warrant liabilities.
• Cash Position: Cash and cash equivalents increased from $5.8 million at year-end 2025 to $116.0 million at June 30, 2026, driven by financing activities totaling $118.4 million.
• Discontinued Operations: The Company ceased development of its eDSP product candidate following the Phase 3 NEAT trial readout in January 2026, leading to the impairment of related assets and the elimination of contingent payment obligations.

Guidance, Outlook, and Risks

Going Concern Warning: Management has concluded that there is substantial doubt about the Company's ability to continue as a going concern for at least twelve months following the issuance of the financial statements. While the Company raised significant capital, the proceeds from the Series C Preferred Stock are subject to conditions (stockholder approval for conversion) that are not entirely within the Company's control. If conversion fails, the Company may be required to make significant cash settlements, potentially depleting resources.

Outlook: The Company's future success depends entirely on the development of LAM-001. A Phase 2b trial for PH-ILD is ongoing (data expected Q1 2028), and a Phase 2 trial for Bronchiolitis Obliterans Syndrome (BOS) is ongoing (data expected Q1 2027).

Key Risks:

• Stockholder Approval: Failure to obtain stockholder approval for the conversion of Series C Preferred Stock could trigger cash settlement obligations.
• Capital Needs: The Company expects to incur significant losses for the foreseeable future and will require additional funding to advance LAM-001.
• Integration: Risks associated with integrating Orphai's operations and personnel.
• Regulatory: Uncertainty regarding the Section 505(b)(2) approval pathway for LAM-001.

Investor Verification Checklist

• Series C Conversion Status: Verify the timeline and likelihood of stockholder approval for the conversion of Series C Preferred Stock to common stock, as this determines potential cash settlement liabilities.
• LAM-001 Trial Progress: Monitor enrollment and interim data from the ongoing Phase 2 trials for PH-ILD and BOS.
• Cash Burn Rate: Assess the sustainability of the $116 million cash balance against the projected operating expenses for the LAM-001 program.
• Warrant Liability: Review the fair value of outstanding Acquisition and Financing Warrants ($6.3 million liability) and their potential dilution upon exercise.
• Reverse Stock Split Adjustments: Ensure all share counts and per-share data are reviewed on a post-split basis (1-for-200 effective split ratio).